Aug. 15 at 12:14 AM
$SCNX [Unfortunate] I was clear to the board that liquidity was a central issue, and the mixed shelf offering made it apparent that equity issuance(s) would be required. I honestly did not expect this placement to be lower than the last; however, we have the
$1.19-1.26 retest that I referenced in July (below). I did not like the way the issuance and earnings were handled - executives with this level of industry experience should be more professional (IMO). That aside-the Company has two (2) FDA approved drugs, commercialization underway
$500M domestic target markets - 100yr management experience, and Arbli has made the Orange book, launched and sales started. Now-we wait to see the sales trajectory, market penetration on Arbli, along with the introduction of Rezenopy (2H-2025). The mixed shelf offering is
$200MILS for a
$10-20Mils Company, trading at 0.2 BV presently.
https://www.stocktitan.net/news/SCNX/scienture-announces-the-shipment-of-launch-quantities-of-arbli-tm-ee0ygj7hth6w.html
